Navigation Links
VisEn Launches New VivoTag(R) 680 XL Fluorescence Molecular Imaging Label
Date:3/11/2010

BEDFORD, Mass., March 11 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new VivoTag® 680 XL fluorescent dye for labeling biomolecules in a broad range of in vitro and in vivo imaging applications.  

VisEn's new near-infrared label, VivoTag® 680 XL, adds an additional imaging label to its current portfolio of VivoTag fluorescent dyes which are used to label specific biomolecules and ligands of interest in a wide variety of in vivo and in vitro imaging applications.  The new VivoTag 680 XL is designed for more efficient labeling of target molecules under standard research conditions, and is optimized for in vivo and cell-based imaging performance, including superior brightness, biocompatibility and stability in biologic environments.  The new VivoTag 680 XL is particularly well suited for labeling of non-quenching, targeted or physiologic agents, and imaging in related applications.  The fluorescence wavelength is matched for biological imaging applications on a range of in vitro and in vivo fluorescence systems, including the VisEn FMT 2500™ LX quantitative tomography system, which also has expanded wavelength capabilities to enable simultaneous imaging of up to four agents and different biomarkers of interest in vivo.

VisEn's proprietary fluorescence imaging agents and labels are designed to provide the industry's broadest and most robust range of biologically-specific imaging readouts.  VisEn offers over 30 different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways.  VisEn agent brands include ProSense®, IntegriSense™, AngioSense™, OsteoSense®, MMPSense™, Annexin-Vivo™, and the FAST™ line of imaging agents including Cat K FAST™ and Cat B FAST™.  VisEn also offers specialized lines of agent labeling platforms, including its proprietary VivoTag® fluorescence labeling dyes and its NanoSpark® nanoparticles, for customized fluorescence agent labeling.  They are all designed and optimized specifically for superior biocompatibility, brightness, stability and performance in biological imaging applications including cell-based and in vivo imaging applications.  

All VisEn agents and labels are designed for in vivo biomarker quantification using VisEn's Fluorescence Molecular Tomography (FMT™) imaging systems, or for general use along with other non-quantitative fluorescence in vivo imaging systems.  VisEn agents are also designed to enable complementary in vitro biomarker readouts in cells and tissues using standard fluorescence microscopy and cellular-based imaging systems.  With a focus on translational research and results, all of VisEn's technologies are designed to generate translational data linking pre-clinical research into clinical medicine.

About VisEn Medical Inc.

VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomography (FMT™) Imaging Systems, provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo.  VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies worldwide in applications including oncology, arthritis, cardiovascular disease, skeletal disorders, and pulmonary disease.

The Company also works with large pharmaceutical and clinical partners to design ranges of tailored molecular imaging agents and applications designed for their specific pre-clinical and clinical research areas.

Additional information can be found at www.visenmedical.com.

SOURCE VisEn Medical Inc.

Back to top

RELATED LINKS
http://www.visenmedical.com

'/>"/>

SOURCE VisEn Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
2. VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE
3. VisEn Acquires Key Fluorescence Agent Intellectual Property Portfolio and Technology Platforms From Bayer Schering Pharma
4. VisEn Launches New Cat B 680 FAST(TM) Fluorescence Molecular Imaging Agent
5. VisEn Launches New Cat B 750 Fast(TM) Fluorescence Molecular Imaging Agent at American Heart Association Meeting
6. VisEn Launches New OsteoSense(R) 800 and VivoTag(R) 800 Fluorescence Molecular Imaging Agents
7. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
8. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
9. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... in the ECG Cables And ECG Leadwires Market owing to ... devices. On the other hand, the Asia-Pacific ... rate during the forecast period. The market players ... plc ( Ireland ), Koninklijke Philips N.V. ( ... ( China ), held major share of the ...
(Date:12/2/2016)... PUNE, India , December 2, 2016 /PRNewswire/ ... research report "In Vitro Diagnostics/IVD Market by Product ... Diagnostics, Hematology), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious ... the global market is valued at USD 60.22 ... grow at a CAGR of 5.5% during the ...
(Date:12/2/2016)... On Thursday, December 1st 2016, ... research, development and innovation in the biopharmaceutical industry at ... in the presence of Sergey Tsyb, Vice Minister of ... , Natalia Sanina, First Vice Chairman of the ... of Roszdravnadzor, National Service of Control in Healthcare, Sergey ...
Breaking Medicine Technology:
(Date:12/2/2016)... Milford, NJ (PRWEB) , ... December 02, 2016 , ... ... Nothing Water has some unique properties including its unmatched natural purity of just 6 ... as clean and crisp. , Nothing Water has been available in several ShopRite and ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health ... has raised $6.0 million in an initial round of funding. The round was ... and their caregivers can receive far better care through the application of the ...
(Date:12/2/2016)... ... December 02, 2016 , ... ‘Tis the season for giving! Today, 20 ... the National Family Partnership and the Drug Enforcement Administration as part of the National ... the 10 winning schools who decorated their campuses with this year’s Red Ribbon Week ...
(Date:11/30/2016)... PALMYRA, Wisconsin (PRWEB) , ... November 30, 2016 ... ... inclusion in the 2016 Deloitte Wisconsin 75, an annual ranking and recognition of ... consecutive year on the list, having ranked from 2008-2016. In addition, Standard Process ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... and stylish design wanted by today’s consumers at an affordable price, is now ... says the new watch is “a game changer” when it comes to the ...
Breaking Medicine News(10 mins):